Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Sheba Medical Center and Israeli Medical Technology Company Nucleai Partner to Accelerate AI Powered Drug Discovery and Clinical Testing

Nucleai Partner
The new strategic partnership will help advance the use of AI-based solutions to aid in the discovery of histological biomarkers such as AI patient care and AI drug discovery and research.

Sheba Medical Center’s ARC Innovation Hub and Israeli medical technology company Nucleai have announced a new strategic data collaboration partnership for the purpose of increasing clinical trial efficacy and improving patient care through the use of AI.

Nucleai is a leading provider of AI-powered precision oncology platforms that leverage tissue datasets to produce insights that aid cancer biomarker analysis and treatment decisions. Nucleai’s software uses computer vision and machine learning algorithms to predict the progress of cancerous tumors as well as the patient’s immune system response based on a visual analysis of the tumor microenvironment.

This new partnership will see Nucleai gain access to millions of patient records provided by Sheba Medical Center, which will include pathology images, clinical data, genomics, and radiomics, along with other data modalities.

Sheba Medical Center and Nucleai have already partnered in the past to identify histological biomarkers that can predict the response of different cancer patients’ bodies to immunotherapy. This was done with the help of Sheba’s Institute of Pathology, a world leader in the field that acts as a center of diagnosis and research for precision medicine.

One success to come out of this previous collaboration, which was led by the Head of the Pathology Institute at Sheba, Prof. Iris Barshack, was a study that demonstrated the prediction efficiency of tumor microenvironment AI-based analysis for breast cancer. These findings were presented at the 2020 American Society of Clinical Oncology (ASCO) Conference.

In a statement released shortly after the announcement, Nucleai stated: “Through the combination of Nucleai and Sheba’s expertise across science, big data, and technology, we continue to transform and revolutionize the application of precision medicine across the healthcare ecosystem.”

News Mar 26.
West Bank and Gaza Medical Professionals Attend a Milestone Sheba Oncology Conference
Highlighting the latest in cancer care, with a particular focus on pediatrics, the Recent Advances in Cancer Care (REACT) 2023 event was attended by over…
Read More
Isenia’s Battle
Isenia’s Battle with Alveolar Sarcoma
At 17, Isenia, a native of Semey, Kazakhstan, noticed a lump on her leg the size of a small apple. Initially, Isenia and her family…
Read More
Colon and Rectal Cancer
News Mar 14.
Sheba Study Indicates Readily-Available Drugs May Prevent Metastasis in Colon and Rectal Cancer Patients
Favorable responses to the treatment were noted by Prof. Shamgar Ben-Eliyahu, a neuroscientist specializing in psychoneuroimmunology (PNI) at TAU’s Sagol School of Neuroscience and School…
Read More